Scarica l'app Stockscreener
34.99
6.55%
2.15
Pre-mercato:
34.99
Precedente Chiudi:
$32.84
Aprire:
$33.34
Volume 24 ore:
500.05K
Relative Volume:
1.01
Capitalizzazione di mercato:
$1.69B
Reddito:
-
Utile/perdita netta:
-
Rapporto P/E:
-
EPS:
-
Flusso di cassa netto:
-
1 W Prestazione:
-0.82%
1M Prestazione:
+6.03%
6M Prestazione:
+133.73%
1 anno Prestazione:
+245.07%
Intervallo 1D:
$32.24
$35.66
Intervallo di 1 settimana:
$31.86
$35.66
Portata 52W:
$5.485
$36.53
Oruka Therapeutics Inc Stock (ORKA) Company Profile
Nome
Oruka Therapeutics Inc
Settore
Industria
Telefono
650-606-7910
Indirizzo
855 OAK GROVE AVE., MENLO PARK
Compare ORKA vs VRTX, REGN, ARGX, ALNY, ONC
| Azioni | Prezzo | Cap. di mercato | Reddito | Reddito netto | Flusso di cassa | EPS |
|---|---|---|---|---|---|---|
ORKA
Oruka Therapeutics Inc
|
34.99 | 1.59B | 0 | 0 | 0 | 0.00 |
|
VRTX
Vertex Pharmaceuticals Inc
|
477.89 | 120.48B | 12.07B | 3.95B | 3.19B | 15.33 |
|
REGN
Regeneron Pharmaceuticals Inc
|
787.50 | 81.05B | 14.34B | 4.50B | 3.77B | 41.56 |
|
ARGX
Argen X Se Adr
|
749.56 | 46.33B | 4.16B | 1.29B | 734.26M | 19.59 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
327.30 | 42.26B | 3.71B | 313.75M | 465.38M | 2.2571 |
|
ONC
Beone Medicines Ltd Adr
|
299.02 | 32.87B | 5.36B | 287.73M | 924.18M | 2.5229 |
Oruka Therapeutics Inc Stock (ORKA) Upgrades & Downgrades
| Data | Azione | Analista | Modifica della valutazione |
|---|---|---|---|
| 2025-12-18 | Iniziato | Piper Sandler | Overweight |
| 2025-11-13 | Iniziato | Jefferies | Buy |
| 2025-10-27 | Iniziato | Guggenheim | Buy |
| 2025-10-13 | Iniziato | Barclays | Overweight |
| 2025-05-22 | Iniziato | BTIG Research | Buy |
| 2025-02-04 | Iniziato | Wolfe Research | Outperform |
| 2024-10-11 | Iniziato | Stifel | Buy |
| 2024-10-07 | Iniziato | H.C. Wainwright | Buy |
| 2024-09-17 | Iniziato | Leerink Partners | Outperform |
| 2024-09-16 | Iniziato | TD Cowen | Buy |
| 2024-09-13 | Iniziato | Jefferies | Buy |
| 2018-02-27 | Iniziato | Ascendiant Capital Markets | Buy |
| 2013-10-09 | Iniziato | Dawson James | Buy |
Mostra tutto
Oruka Therapeutics Inc Borsa (ORKA) Ultime notizie
Oruka Therapeutics, Inc. (NASDAQ:ORKA) Short Interest Down 17.2% in February - MarketBeat
Is Oruka Therapeutics Inc. forming bullish engulfing patternsJuly 2025 Rallies & Smart Allocation Stock Reports - mfd.ru
Oruka Therapeutics Inc expected to post a loss of 63 cents a shareEarnings Preview - TradingView
Oruka Therapeutics (NASDAQ:ORKA) Upgraded at Wall Street Zen - Defense World
Oruka Therapeutics, Inc. (ORKA) Stock Analysis: A 62% Upside Potential in the Biotech Arena - DirectorsTalk Interviews
Oruka Therapeutics (ORKA) Expected to Announce Earnings on Thursday - Defense World
Oruka Therapeutics stock hits 52-week high at 36.53 USD By Investing.com - Investing.com Australia
Oruka Therapeutics (NASDAQ:ORKA) Reaches New 52-Week HighWhat's Next? - MarketBeat
Oruka Therapeutics stock hits 52-week high at 36.53 USD - Investing.com
Oruka Therapeutics: A Potential Future Psoriasis Play (NASDAQ:ORKA) - Seeking Alpha
Empirical Financial Services LLC d.b.a. Empirical Wealth Management Acquires New Holdings in Oruka Therapeutics, Inc. $ORKA - Defense World
Oruka Therapeutics, Inc. (NASDAQ:ORKA) Receives Consensus Rating of “Moderate Buy” from Brokerages - Defense World
RTW INVESTMENTS, LP Expands Stake in Oruka Therapeutics Inc - GuruFocus
How Oruka Therapeutics Inc. stock performs in high volatility marketsJuly 2025 Summary & Stepwise Trade Signal Guides - mfd.ru
Oruka Therapeutics, Inc. (ORKA) Stock Analysis: A Promising 71.70% Potential Upside In Biotech Innovation - DirectorsTalk Interviews
Will Oruka Therapeutics Inc outperform tech stocksJuly 2025 Chart Watch & Low Risk Entry Point Guides - baoquankhu1.vn
Evaluating Oruka Therapeutics (ORKA) Valuation After Strong Recent Share Price Momentum - Yahoo Finance
Big Money Moves: Whats the beta of Uniti Group Inc stockGap Up & Risk Managed Investment Signals - baoquankhu1.vn
Aug Summary: Is Oruka Therapeutics Incs ROE strong enoughJuly 2025 Retail & Expert Approved Momentum Ideas - baoquankhu1.vn
Published on: 2026-02-15 16:13:39 - mfd.ru
Oruka Therapeutics, Inc. (ORKA) Stock Analysis: Promising 70% Upside Potential In Biotech - DirectorsTalk Interviews
How cyclical is Oruka Therapeutics Inc.’s revenue streamJuly 2025 Sector Moves & Verified Chart Pattern Trade Signals - mfd.ru
Candriam S.C.A. Buys 250,296 Shares of Oruka Therapeutics, Inc. $ORKA - MarketBeat
Is Oruka Therapeutics Inc. stock a contrarian buyWeekly Earnings Recap & Weekly Market Pulse Updates - mfd.ru
Will Oruka Therapeutics Inc. stock remain a Wall Street favoriteJuly 2025 Action & Accurate Buy Signal Alerts - mfd.ru
Oruka Therapeutics to Participate in Multiple Upcoming Conferences - The Manila Times
Oruka Therapeutics, Inc. (ORKA) Stock Analysis: A Promising 77% Upside Potential in the Biotech Sector - DirectorsTalk Interviews
Dow Update: What is Oruka Therapeutics Incs book value per share2025 Retail Activity & Verified Swing Trading Watchlists - baoquankhu1.vn
Clear Street says AbbVie move further validates Oruka Therapeutics’ strategy - TipRanks
Oruka Therapeutics, Inc. (NASDAQ:ORKA) Short Interest Down 31.3% in January - MarketBeat
Oruka Therapeutics, Inc. (NASDAQ:ORKA) Given Average Rating of "Moderate Buy" by Analysts - MarketBeat
Oruka Therapeutics, Inc. (NASDAQ:ORKA) Given Average Rating of “Moderate Buy” by Analysts - Defense World
Oruka Therapeutics, Inc. (ORKA) Stock Report: Biotechnology Pioneer Poised for 57.87% Upside - DirectorsTalk Interviews
Portfolio Update: Is Global Blue Group Holding AG Equity Warrant stock a top performer YTDQuarterly Growth Report & Long Hold Capital Preservation Plans - baoquankhu1.vn
How cyclical is Oruka Therapeutics Incs revenue streamWeekly Investment Recap & Safe Capital Growth Stock Tips - baoquankhu1.vn
How Early ORKA-002 Dosing Data At Oruka Therapeutics (ORKA) Has Changed Its Investment Story - simplywall.st
H.C. Wainwright Maintains Oruka Therapeutics(ORKA.US) With Buy Rating, Maintains Target Price $40 - 富途牛牛
Oruka Therapeutics (NASDAQ:ORKA) Shares Gap DownHere's What Happened - MarketBeat
Market Outlook: Does Oruka Therapeutics Inc stock have upside surprise potential2025 Market Overview & Stock Portfolio Risk Management - baoquankhu1.vn
Fed Meeting: Will Oruka Therapeutics Inc outperform tech stocksJuly 2025 Reactions & Entry Point Confirmation Signals - baoquankhu1.vn
RSI Check: Can GLPG outperform under higher oil pricesJuly 2025 Highlights & Daily Market Momentum Tracking - baoquankhu1.vn
Oruka Therapeutics (NASDAQ:ORKA) Sets New 52-Week HighWhat's Next? - MarketBeat
Oruka Therapeutics, Inc. (ORKA) Stock Price History & Data - Traders Union
Gains Report: Will Oruka Therapeutics Inc benefit from AI trendsGold Moves & Reliable Momentum Entry Alerts - baoquankhu1.vn
Aug Opening: Will ARTV outperform the market in YEAR2025 Major Catalysts & Low Drawdown Trading Techniques - baoquankhu1.vn
Assessing Oruka Therapeutics (ORKA) Valuation After Encouraging ORKA 002 Phase 1 Trial Results - Sahm
Oruka Therapeutics, Inc. (NASDAQ:ORKA) Short Interest Update - MarketBeat
Joana Goncalves Sells 7,000 Shares of Oruka Therapeutics (NASDAQ:ORKA) Stock - MarketBeat
Oruka Therapeutics stock hits 52-week high at 32.65 USD By Investing.com - Investing.com Nigeria
Oruka Therapeutics (ORKA) Is Up 23.1% After Extended-Dosing IL-17 Data for ORKA-002What's Changed - Sahm
Oruka Therapeutics (NASDAQ:ORKA) Sets New 12-Month HighHere's Why - MarketBeat
Oruka Therapeutics Inc Azioni (ORKA) Dati Finanziari
Non sono disponibili dati finanziari per Oruka Therapeutics Inc (ORKA). Controlla altri titoli per ulteriori informazioni.
Reddito
Reddito netto
Flusso di cassa
EPS
Oruka Therapeutics Inc Azioni (ORKA) insider trading
| Commercio interno | Relazione | Data | Transazione | Costo | #Azioni | Valore ($) | #Azioni Totale |
|---|---|---|---|---|---|---|---|
| Sandler Laura Lee | Chief Operating Officer |
Mar 02 '26 |
Sale |
33.56 |
5,000 |
167,822 |
237,584 |
| Goncalves Joana | Chief Medical Officer |
Feb 17 '26 |
Option Exercise |
7.32 |
7,000 |
51,240 |
41,018 |
| Goncalves Joana | Chief Medical Officer |
Feb 17 '26 |
Sale |
32.37 |
7,000 |
226,559 |
34,018 |
| Goncalves Joana | Chief Medical Officer |
Jan 15 '26 |
Option Exercise |
7.32 |
7,000 |
51,240 |
8,518 |
| Goncalves Joana | Chief Medical Officer |
Jan 15 '26 |
Sale |
31.81 |
7,000 |
222,704 |
1,518 |
| Sandler Laura Lee | Chief Operating Officer |
Jan 02 '26 |
Option Exercise |
7.80 |
5,000 |
39,000 |
218,084 |
| Sandler Laura Lee | Chief Operating Officer |
Jan 02 '26 |
Sale |
28.52 |
13,000 |
370,795 |
205,084 |
0.11%
6.00%
Apri su Yahoo
|
Apri su Google
|
Aperto in Finviz
|
Apri in MarketWatch
|
Aperto a EDGAR
|
Aperto su Reuters
Capitalizzazione:
|
Volume (24 ore):